Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) has announced that its subsidiary, Shangyao Dongying (Jiangsu) Pharmaceutical Co., Ltd., recently received a Drug Registration Certificate from the National Medical Products Administration.

The certificate, numbered 2026S03379, grants approval for the production of Isavuconazonium Sulfate for Injection.

The drug is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients and pediatric patients aged 1 year and older.